Pharmaceutical Contract Manufacturing Market-Technological Advancement Accelerates the Growth of the Market

Also known as Contract Development and Manufacturing Organization (CDMO), Contract Manufacturing Organization (CMO), is a company serves another companies in the pharmaceutical industry, on a contract basis. The company provide comprehensive services from drug development through drug manufacturing. Many of the pharmaceutical companies are now outsourcing various business aspects. This helps the company to focus on drug discovery, and drug marketing.

Contract pharmaceutical manufacturing has evolved largely from last few years. Manufacturing of generic as well as branded drugs, thus reducing the demand and supply gap. Generic drugs are most commonly preferred by the patients as they are cheaper than the branded drugs. Growing demand for generic drugs, and competition and economics of production and trade are major drivers for the growth of the market. Additionally, urge of new product development through technological advancement also fuels the market growth. However, the market is restrained by factors such as high cost of labour, structural changes in industry and employment, standardization and interoperability, and others.

According to Bloomberg, in 2020, USD 60 billion of drug sales are expected to be threatened by generics. In 2016, adalimumab, ledipasvir/sofosbuvir, rituximab, bevacizumab, trastuzumab are the drugs that lost patents.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1532 .

Key players in the Global Pharmaceutical Contract Manufacturing market

Catalant, Boehringer Ingelheim, Lonza AG, Grifols International, S.A, AbbVie Inc, Patheon Inc., Vetter, Pharmaceutical Product Development and others are key players in the market.

Key Developments

Strategic approaches adopted help the major players to sustain their growth in the market and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.

Boehringer Ingelheim

Boehringer Ingelheim is focused on research, development, and manufacturing of new medications with high therapeutic value for people and animals. The company has a vast product portfolio in the healthcare industry. The company also has wide geographic presence as it operates across the world. With the huge workforce of around 50,000+ employees. They have a significant presence in North America, Europe, the Middle East & Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.

September, 2017: Boehringer Ingelheim received positive CHMP opinion for adalimumab biosimilar CYLTEZO
September, 2017: Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
August, 2017: Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Lonza AG

September, 2017: Lonza AG and Portola Pharmaceuticals sign strategic long-term manufacturing agreement to secure supply of AndexXa
August, 2017: Lonza AG to increase and expand capabilities for drug product services for parenteral dosage forms
August, 2017: Lonza AG acquired Micro-Macinazione to become a global leader in micronization capacity and capabilities
Dalton Pharma Services

Dalton Pharma Services is a company offering full range of services in-house such as drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing and/or dosage form manufacturing

September, 2017: Dalton Pharma Services announced a drug development and GMP manufacturing services agreement with Arch Biopartners
February, 2017: Dalton Pharma Services Wins 2017 CMO leadership awards
January, 2017: Dalton Pharma Services announced drug development and manufacturing services agreement with Cerium Pharmaceuticals
December, 2016: Dalton Pharma Services entered into agreement with the USAMMDA in support of the US Army’s Drug Development Program
August, 2017: Dalton Pharma Services announced the completion of a major expansion with the completion of a USD 5 million expansion in sterile filling and API manufacturing at its cGMP facility in Toronto, Canada.
June 2016: Dalton Pharma Services announced addition of flow chemistry technology
Browse Complete Report at https://www.marketresearchfuture.com/reports/pharmaceutical-contract-manufacturing-market-1532 .

Competitive Landscape

There are numerous players operating in this global pharmaceutical contract manufacturing market. Many organizations especially in North American and Asian region rely on contract manufacturing units for drugs, devices and equipment’s in the healthcare industry. As there are plenty of large and small market players available, it‘s very tricky to analyses their market shares in the global market, but through this market study some major players operating in this market.

Pharmaceutical Contract Manufacturing Market in Asia Pacific

Asia Pacific exhibits tremendous growth opportunities in the market which is attributed to the extensive growth of pharmaceutical industry, increasing number of key players in the market, and rising healthcare expenditure. According to India Brand Equity Foundation, the Indian Pharmaceutical market is expected to grow to USD 55 billion by 2020, thereby emerging as the sixth largest pharmaceutical market globally by absolute size. Branded generics are expected to constitute nearly 80 per cent of the market share in terms of revenues.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.